Nurami Medical has completed patient enrollment in its ongoing First-in-Human pilot study evaluating ArtiFix® across clinical sites in Europe.
ArtiFix® represents the next step in Nurami Medical’s dural repair portfolio. The investigational adhesive graft is designed to support sutureless dural repair in cranial and spinal procedures.
The clinical development of ArtiFix® is supported by funding from the European Innovation Council (EIC), recognizing the potential of Nurami Medical’s technology to advance soft tissue repair through innovative, fully synthetic biomaterials.
With enrollment now complete, patient follow-up and clinical evaluation remain ongoing. In parallel, Nurami Medical is evaluating potential clinical sites across the United States and Europe for a future multicenter clinical study.
